<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45238">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01921426</url>
  </required_header>
  <id_info>
    <org_study_id>GT-001</org_study_id>
    <nct_id>NCT01921426</nct_id>
  </id_info>
  <brief_title>A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head &amp; Neck</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and the highest dose of
      GC4419 that can be given to patients with squamous cell cancer of the head and neck who are
      receiving standard radiation therapy and chemotherapy.  This study will also evaluate GC4419
      for the following:

        -  Effect on the incidence and severity of radiation induced oral mucositis;

        -  Effect on the response rate of squamous cell cancer of the head and neck who are
           receiving radiation therapy and chemotherapy;

        -  Total concentrations of GC4419 that can be achieved in the blood;

        -  Changes in proteins and genetics associated with oral mucositis;

        -  Impact on delayed toxicities of radiation (dry mouth and reduced ability to fully open
           the mouth);

        -  Observe changes in genetic and molecular markers of oral mucositis;

        -  Observe the usage of extra health resources (e.g., unplanned ER visits, feeding tube
           use, etc.) of study patients;

        -  Assess the overall quality of life in study patients with oral mucositis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Frequency and Severity of Adverse Events Resulting from GC4419</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>GC4419 will be evaluated to determine safety, tolerability, and the maximum tolerated dose of GC4419 that can be administered to patients with squamous cell cancer of the head and neck who are receiving concurrent radiation (50-70 Gy, administered daily x 5 [M-F], in 2.0-2.2 Gy fractions) and chemotherapy (cisplatin, 80-100mg/m2, q3 weeks).  Patients will receive 14 doses of GC4419, which correspond to the first 14 doses of radiation.  Dose limiting toxicity will be evaluated through the first 21 days on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Exposure to GC4419 (Pharmacokinetic Profile)</measure>
    <time_frame>18 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the pharmacokinetic profile, including the extent and rate of exposure (e.g., maximum concentration, total exposure, half life, time to maximum concentration, accumulation, etc.) to GC4419, as well as GC4419 kinetics (e.g., half-life, in patients with squamous cell carcinoma of the head and neck receiving GC4419 when administered in combination with standard chemoradiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Mucositis</measure>
    <time_frame>49 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the incidence, severity, time to first onset and duration of oral mucositis in patients with squamous cell carcinoma of the head and neck receiving GC4419 when administered in combination with standard chemoradiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Effect</measure>
    <time_frame>14 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Preliminarily assess the tumor response to standard chemoradiation when administered in conjunction with GC4419 at approximately 1 year following completion of chemoradiation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Profile</measure>
    <time_frame>49 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the pharmacodynamic profile of GC4419 in patients with squamous cell carcinoma of the head and neck receiving GC4419 when administered in combination with standard chemoradiation by observing the changes in proteins and genetic markers associated oral mucositis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Squamous Cell Carcinoma of the Oral Cavity</condition>
  <condition>Squamous Cell Carcinoma of the Oropharynx</condition>
  <arm_group>
    <arm_group_label>GC4419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy.  Each dose will be given intravenously over 60 minutes.  The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4419</intervention_name>
    <arm_group_label>GC4419</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically-confirmed diagnosis of squamous cell carcinoma of the head and neck
             (SCCHN), defined as SCC of the oral cavity or oropharynx, that will be treated with
             standard cisplatin and Intensity-Modulated Radiation Therapy (IMRT)

          -  Males or females aged 18 years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2

          -  Adequate bone marrow, liver and kidney function

          -  Negative serum pregnancy test for females of childbearing potential

          -  Properly obtained written informed consent

        Exclusion Criteria:

          -  Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, salivary glands or
             unknown primary tumor

          -  Metastatic disease (Stage IV C)

          -  Prior chemotherapy for SCCHN and/or radiotherapy to the region of the study cancer or

          -  Receiving any agent classified as an antioxidant

          -  History of malignant tumors other than SCCHN within the last 5 years, except
             non-melanoma skin cancer or curatively excised in situ cervical carcinoma

          -  Active infectious disease excluding oral candidiasis

          -  Presence of oral mucositis at study entry

          -  Chronic immunosuppression

          -  Known history of HIV or active hepatitis B/C )

          -  Prior history of hearing impairment

          -  Use of investigational agent within 30 days of study entry

          -  Known allergies or intolerance to cisplatin and similar platinum-containing compounds

          -  Requirement for concurrent treatment with nitrates or other drugs that may, in the
             judgment of the treating investigator, create a risk for a precipitous decrease in
             blood pressure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon T. Holmlund, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galera Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madhavi Venigalla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lakeland Regional Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weining Zhen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Adkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pardip Pathare, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwalk Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjiv Agarwala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Kunos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summa Health System- Cooper Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuhchyau Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Buatti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aftab Mahmood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Specialists of South Texas, P.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larisa Greenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Penn Allegheny Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Long, ANP-BC</last_name>
      <phone>203-852-2996</phone>
      <email>jennifer.long@norwalkhealth.org</email>
    </contact>
    <investigator>
      <last_name>Pardip Pathare, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin S. Stewart, RN PhD OCN</last_name>
      <phone>863-904-1877</phone>
      <email>robin.stewart@lrmc.com</email>
    </contact>
    <investigator>
      <last_name>Madhavi Venigalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>John Buatti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey Johnson</last_name>
      <phone>314-362-0208</phone>
      <email>ljohnson@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Adkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Filler-Katz, RN BSN</last_name>
      <phone>402-552-2790</phone>
      <email>afillerkatz@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Weining Zhen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Smudzin, BS</last_name>
      <phone>585-275-7848</phone>
      <email>therese_smudzin@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Health System- Cooper Cancer Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Kaplan, RN OCN</last_name>
      <phone>330-375-6121</phone>
      <email>kaplanlm@summahealth.org</email>
    </contact>
    <investigator>
      <last_name>Charles Kunos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Center</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Dancho, RN, CURN, OCN</last_name>
      <phone>484-503-4150</phone>
      <email>Stacie.Dancho@sluhn.org</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Agarwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hebda, BS, CCRC</last_name>
      <phone>412-359-4046</phone>
      <email>shebda@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Larisa Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of South Texas, P.A.</name>
      <address>
        <city>Corpus Christie</city>
        <state>Texas</state>
        <zip>78412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Powell, CCRC</last_name>
      <phone>361-993-3456</phone>
      <phone_ext>140</phone_ext>
      <email>kpowell@corpuschristicancer.com</email>
    </contact>
    <investigator>
      <last_name>Aftab Mahmood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma of the Head and Neck</keyword>
  <keyword>Oral Cavity</keyword>
  <keyword>Oropharynx</keyword>
  <keyword>Radiation</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Oral Mucositis</keyword>
  <keyword>Superoxide Dismutase</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
